Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics

Palliative Radiotherapy with Concomitant and Maintenance Gefitinib for the Management of Locally Advanced Adenocarcinoma Lung Patients Unfit For Radical Treatment

“…Both radiation-induced pulmonary pneumonitis and lung fibrosis were also noticed in 15% and 6% of the patients respectively, with no grade 3 or 4 toxicity. Skin rashes, diarrhoea and haematological toxicities were less while late complications like radiation-induced pneumonitis and lung fibrosis were more in present study as compared to study by Wang et al 5 Difference in rate of complications was due to use of conventional fraction and curative intent of treatment by Wang et al 14 On CECT chest, sixty eight percent patients had shown partial response to the treatment while 32% patients had maintained stable disease status at first follow up. Not even a single patient had shown progressive disease nor any patient died in 1 month following the treatment.…”

“…Epithelial Growth Factor Receptor (EGFR). 5,6 Drugs like gefitinib acting as EGFRTyrosine kinase inhibitors (TKIs) have already proven their efficacy in the management of adenocarcinoma lung. 7 Gefitinib has radiosensitizing effect in EGFR mutation positive lung adenocarcinoma and the prevalence of this mutation in adenocarcinoma is ~50% of Asian patients.…”

Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis

“…Here, we report the results of a preliminary screening performed on a series of IPF and lung cancer cases aimed at comparing the expression of a panel of key molecules whose pathways are known to drive NSCLC onset and progression [3]. In detail, we checked the status of the EGFR and MET receptors together with that of the downstream transducer KRAS and of intracytoplasmic signaling molecules as the mTOR, the PTEN, and the ERM protein complex.…”

“…Kinases and their inhibitors, phosphatases, are key regulators of several cellular functions, and their appropriate activity is required for the cellular homeostasis; on the contrary, their aberrant activation is crucial in driving oncogenesis. The concept that cancer-mutated kinases molecularly mark “druggable” targets has resulted in intensive efforts to survey the kinome across a wide spectrum of human tumor types for mutations and to the development of several targeted inhibitors [3].…”

Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review

“…These are often tyrosine kinase inhibitors (TKI) [1]. Currently, TKI are approved for metastasized NSCLC patients with an activating epidermal growth factor receptor (EGFR) mutation or an anaplastic lymphoma kinase (ALK) rearrangement, either as first line or beyond [2,3].…”